Dear Editor:

We read with great interest the study by Zou et al.[@bib1] Their results are interesting and important, but we do have some concerns about them.

In this study, the authors found that liver injury in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chronic hepatitis B virus (HBV) coinfection was associated with severe illness and an overall poor prognosis. However, these results are built on a single cohort, meaning that coronavirus disease 2019 (COVID-19) patients with HBV coinfection have not been compared with patients with SARS-CoV-2 infection alone. One of the major concerns for clinicians is whether COVID-19 patients with a specific disease have a more severe illness and a worse prognosis than those without, which is not provided in the current study.

In terms of the data presented in this study, the results of HBV DNA test have not been given, and therefore the clinical stage of included patients cannot be determined clearly. Because most patients in this study are likely to be classified as patients with hepatitis B e antigen--negative chronic HBV infection,[@bib2] the clinical outcomes of patients with acute HBV infection or with active HBV replication remain unclear. Furthermore, the authors described the information of patients who took oral antivirals on admission. It is not clear whether these patients continued to take antivirals during hospitalization, which may affect patients' clinical outcomes. We also found that many antivirals, antibiotics, and steroids were used for treatment in this study, and the use of these drugs may further influence the results; drug-induced liver injury cannot be ruled out in this study.[@bib3]

We suspect that immune dysfunction caused by chronic HBV infection may play an important role in the progression of disease in COVID-19 patients. Several studies showed that HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms.[@bib2] Furthermore, depressed immunity is manifested by decreased immune cell populations, and reduced CD4 (+) and CD8 (+) T-cell counts were predictive of disease progression in patients with COVID-19.[@bib4] Thus, the presence of coinfection leading to possible immune disorders and suppression may influence the disease progression in COVID-19 patients. Because the current study did not present data on patients' immune function, more research is needed to confirm this hypothesis and explain the specific mechanism in the future.
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